Alexion Pharmaceuticals Inc (ALXN)

NASDAQ
182.50
0.00(0.00%)
  • Volume:
    0
  • Day's Range:
    180.13 - 182.67
  • 52 wk Range:
    169.94 - 187.45

ALXN Overview

Prev. Close
182.5
Day's Range
180.13-182.67
Revenue
6.26B
Open
181.04
52 wk Range
169.94-187.45
EPS
3.05
Volume
0
Market Cap
36.08B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
4,279,854
P/E Ratio
59.91
Beta
1.3
1-Year Change
0%
Shares Outstanding
199,613,272
Next Earnings Date
-
What is your sentiment on Alexion?
or
Market is currently closed. Voting is open during market hours.

Alexion Pharmaceuticals Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade
  • FTSE 100 remains upbeat, US seen higher
    • ByProactive Investors-

    • FTSE 100 up, but off best levels • US stocks seen higher, more key results due • IMI (LON:IMI) results please analysts FTSE 100 held in positive territory in early...

Alexion Pharmaceuticals Inc Analysis

Alexion Pharmaceuticals Inc Company Profile

Alexion Pharmaceuticals Inc Company Profile

Employees
3837

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has a collaboration and licence agreement with Neurimmune AG. The company was incorporated in 1992 and is based in Boston, Massachusetts with an additional office in Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyBuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Buy
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Buy
  • Bullish guys thanks you
    0
    • Vote bullish thanks you management services
      0
      • Is it time to buy ALXN stock noe?
        0
        • I think so but I'm not sure why its not moving altho theres a deal with AstraZeneca valuing it at 175 per share
          0
        • 👍🏼
          0